<DOC>
	<DOC>NCT00937391</DOC>
	<brief_summary>The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to &lt; 2 years of age</brief_summary>
	<brief_title>Contrast-enhanced MRI in Children 2 Months to &lt;2 Years</brief_title>
	<detailed_description>Safety issues are addressed in the AE section</detailed_description>
	<criteria>Age: 2 months to &lt; 2 years (23 months) Participants (male/female) who are scheduled to undergo gadoliniumenhanced MRI Able to comply with the study procedures Clinical unstable participants (eg, intensive care unit) Renal Insufficiency Participants undergoing chemotherapy &lt;/= 48 hours prior to and up to 24 hours after the administration of Magnevist.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>MRI agents</keyword>
	<keyword>Magnevist</keyword>
</DOC>